Journal of Urban Health

, Volume 81, Issue 2, pp 278–290 | Cite as

Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the beck depression inventory

  • Elizabeth T. Golub
  • Mary Latka
  • Holly Hagan
  • Jennifer R. Havens
  • Sharon M. Hudson
  • Farzana Kapadia
  • Jennifer V. Campbell
  • Richard S. Garfein
  • David L. Thomas
  • Steffanie A. Strathdee
Original Articles: Various Topics

Abstract

The prevalence of depression is high among injection drug users (IDUs) and among those infected with the hepatitis C virus (HCV). Moreover, one of the drugs used in the standard treatment for HCV infection (interferon) has been known to exacerbate, underlying psychiatric disorders such as depression and has been associated with the development of major, depressive disorder among HCV-infected patients. For these reasons, the most recent National Institutes of Health consensus statement on the management of HCV infection recommends the identification and treatment of depression prior to the start of HCV treatment. This study aimed to examine the extent of current moderate/severe depressive symptoms in a cohort of HCV-infected IDUs as measured by two screening tools, the Center for Epidemiologic Studies Depression Scale (CES-D) and the Beck Depression Inventory (BDI). Subjects were participants in a multisite behavioral intervention trial among HCV-seropositive, human immunodeficiency virus-negative IDUs aged 18–35 years; the trial was designed to prevent secondary transmission of HCV and to enhance uptake of HCV treatment. Baseline data on demographics, risk behaviors, depression, alcohol use, and health care utilization were measured via audio computer-assisted self-interview. A factor analysis was conducted on each scale to examine the clustering of items used in each to measure depressive symptoms. Baseline depressive symptoms, as measured via the CES-D and the BDI, were also compared using Pearson’s correlation coefficient. Of 193 HCV-infected individuals enrolled to date, 75,6% were male, and 65.3% were white. Median age was 25.8 years. Factor analyses revealed that these scales measured depression differently; a distinct somatic component was present in the BDI, but not the CES-D. Using cutoff scores of 23 for the CES-D and 19 for the BDI, 44.0% and 41.5% of the participants were identified as having moderate/severe depressive symptoms, respectively. Over half (56.0%) were identified as having depressive symptoms

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Centers for Disease Control and Prevention. Viral Hepatitis, and Injection Drug Users. 2002. Available at: www.cdc.gov/idu.Google Scholar
  2. 2.
    Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–456.CrossRefPubMedGoogle Scholar
  3. 3.
    Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002 Jun 10–12; 19(3):1–41.Google Scholar
  4. 4.
    Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211–215.CrossRefPubMedGoogle Scholar
  5. 5.
    Management of Hepatitis C. NIH Consensus Statement 1997 Mar 24–26; 15(3):1–41.Google Scholar
  6. 6.
    Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942–947.CrossRefPubMedGoogle Scholar
  7. 7.
    Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237–241.CrossRefPubMedGoogle Scholar
  8. 8.
    Khantizian EJ, Treece C. DSM-III psychiatric diagnoses of narcotic addicts. Arch Gen Psychiatry. 1985;42:1067–1071.Google Scholar
  9. 9.
    Ross HE, Glaser FB, Germanson F. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45:1023–1031.PubMedGoogle Scholar
  10. 10.
    Rounsaville BJ, Weissman MM, Kleber HD, et al. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry. 1982;39:161–166.PubMedGoogle Scholar
  11. 11.
    Johnson ME, Fisher DG, Fenaughty, A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol. 1998;93:785–789.CrossRefPubMedGoogle Scholar
  12. 12.
    Knowlton AR, Latkin CA, Schroeder JR, Hoover DR, Ensminger M, Celentano DD. Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care. 2001;13:549–559.CrossRefPubMedGoogle Scholar
  13. 13.
    Dinwiddie SH, Reich T, Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry. 1992;53:364–369.PubMedGoogle Scholar
  14. 14.
    American Psychiatric, Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Association; 1994.Google Scholar
  15. 15.
    Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18:331–337.CrossRefPubMedGoogle Scholar
  16. 16.
    Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry. 2003;160:1659–1662.CrossRefPubMedGoogle Scholar
  17. 17.
    Swartz MS, Swanson JW, Hannon MJ, et al. Blood-borne infections and persons with mental illness: regular sources of medical care among persons with severe, mental illness at risk of hepatitis C infection. Psychiatr Serv. 2003;54:854–859.CrossRefPubMedGoogle Scholar
  18. 18.
    Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol. 2000;12:505–509.PubMedGoogle Scholar
  19. 19.
    Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002;14:367–378.CrossRefPubMedGoogle Scholar
  20. 20.
    Newman JC, Des J, Turner CF, Gribble J, Cooley P, Paone, D. The differential effects of face-to-face and computer interview modes. Am J Public Health. 2002;92:294–297.PubMedCrossRefGoogle Scholar
  21. 21.
    Metzger DS, Koblin B, Turner C, et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000;152:99–106.CrossRefPubMedGoogle Scholar
  22. 22.
    Centers for Disease Control and Prevention. HIV counseling, testing and referral standards and guidelines. Atlanta, GA. US Department of Health and Human Services, Public Health Service, CDC, 1994.Google Scholar
  23. 23.
    Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385–401.Google Scholar
  24. 24.
    Clark CH, Mahoney JS, Clark DJ, Eriksen LR. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs. 2002;40:361–369.CrossRefPubMedGoogle Scholar
  25. 25.
    Roberts RE. Reliability of the CES-D scale in different ethnic contexts. Psychiatry Res. 1980;2:125–134.CrossRefPubMedGoogle Scholar
  26. 26.
    Weissman MW, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations, a validation study. Am J Epidemiol. 1977;106:203–214.PubMedGoogle Scholar
  27. 27.
    Perdue T, Hagan H, Thiede H, Valleroy L. Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Educ Prev. 2003;15:81–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.PubMedGoogle Scholar
  29. 29.
    Joe GW, Knezek L, Watson D, Simpson DD. Depression and decision-making among intravenous drug users. Psychol Rep. 1991;68:339–347.CrossRefPubMedGoogle Scholar
  30. 30.
    Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: 25 years of evaluation. Clin Psychol Rev. 1988;8:77–100.CrossRefGoogle Scholar
  31. 31.
    Shaw BF, Steer RA, Beck AT, Schut J. The structure of depression in heroin addicts. Br J Addict Alcohol Other Drugs. 1979;74:295–303.PubMedGoogle Scholar
  32. 32.
    Reynolds WM, Gould JW. A psychometric investigation of the standard and short form Beck Depression Inventory. J Consult Clin Psychol. 1981;49306–307.CrossRefPubMedGoogle Scholar
  33. 33.
    Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol. 2000;15:300–303.CrossRefPubMedGoogle Scholar
  34. 34.
    Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966.CrossRefPubMedGoogle Scholar
  35. 35.
    Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194–198.PubMedGoogle Scholar
  36. 36.
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment a dherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451.CrossRefPubMedGoogle Scholar

Copyright information

© The New York Academy of Medicine 2004

Authors and Affiliations

  • Elizabeth T. Golub
    • 8
  • Mary Latka
    • 1
  • Holly Hagan
    • 2
  • Jennifer R. Havens
    • 8
  • Sharon M. Hudson
    • 3
  • Farzana Kapadia
    • 1
  • Jennifer V. Campbell
    • 4
  • Richard S. Garfein
    • 5
  • David L. Thomas
    • 6
  • Steffanie A. Strathdee
    • 8
    • 7
  1. 1.New York Academy of MedicineCenter for Urban Epidemiologic StudiesNew York
  2. 2.National Development and Research InstitutesCenter for Drug Use and HIV ResearchNew York
  3. 3.Health Research AssociationLos AngelesCalifornia
  4. 4.Public Health-Seattle and King CountySeattle
  5. 5.Division of HIV/AIDS Prevention, Epidemiology BranchCenters for Disease Control and PreventionAtlanta
  6. 6.Johns Hopkins University School of MedicineBaltimore
  7. 7.University of CaliforniaSan Diego
  8. 8.Department of Epidemiology Infectious Diseases ProgramJohns Hopkins Bloomberg School of Public HealthBaltimore

Personalised recommendations